Want to commission a custom market research to suit your needs? We are here to help. Let us know.
Global Public Health Partnering 2012-2018: Deal trends, players and financials provides comprehensive understanding and unprecedented access to the public health partnering deals and agreements entered into by the worlds leading healthcare companies
Global Public Health Partnering 2012 to 2018 provides the full collection of Public Health disease deals signed between the world’s pharmaceutical and biotechnology companies since 2012.
Trends in Public Health partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Public Health partnering agreement structure
Public Health partnering contract documents
Top Public Health deals by value
Most active Public Health dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Public Health disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Public Health deals.
The report presents financial deal terms values for Public Health deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Public Health dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Public Health dealmaking since 2012 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Public Health deals since 2012. Deals are listed by headline value. The chapter includes the top 25 most active Public Health dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Public Health deals since 2012 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Public Health partnering deals by specific Public Health target announced since 2012. The chapter is organized by specific Public Health therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Public Health partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Public Health partnering and dealmaking since 2012.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Public Health technologies and products.
Global Public Health Partnering 2012 to 2018 is intended to provide the reader with an in-depth understanding and access to Public Health trends and structure of deals entered into by leading companies worldwide.
Global Public Health Partnering 2012 to 2018 includes:
Trends in Public Health dealmaking in the biopharma industry since 2012
Analysis of Public Health deal structure
Access to headline, upfront, milestone and royalty data
Access to hundreds of Public Health deal contract documents
Comprehensive access to over 3500 Public Health deal records
The leading Public Health deals by value since 2012
Most active Public Health dealmakers since 2012
The report includes deals for the following indications: Addiction, Smoking, Drugs, Alcohol, Health education, Obesity, Preventative medicine, plus other public health indications.
In Global Public Health Partnering 2012 to 2018, available deals and contracts are listed by:
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Public Health Partnering 2012-2018 report provides comprehensive access to available deals and contract documents for over 200 public health deals. Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Global Public Health Partnering 2012 to 2018 provides the reader with the following key benefits:
In-depth understanding of Public Health deal trends since 2012
Access Public Health deal headline, upfront, milestone and royalty data
Research hundreds of actual contracts between Public Health partner companies
Comprehensive access to over 750 links to actual Public Health deals entered into by the world’s biopharma companies
Indepth review of Public Health deals entered into by the top 25 most active dealmakers
Benchmark the key deal terms companies have agreed in previous deals
Identify key terms under which companies partner Public Health opportunities
Uncover companies actively partnering Public Health opportunities
Chapter 1 – Introduction
Chapter 2 – Trends in Public Health dealmaking
2.2. Public Health partnering over the years
2.3. Public Health partnering by deal type
2.4. Public Health partnering by industry sector
2.5. Public Health partnering by stage of development
2.6. Public Health partnering by technology type
2.7. Public Health partnering by therapeutic indication
Chapter 3 –Financial deal terms for Public Health partnering
3.2. Disclosed financials terms for Public Health partnering
3.3. Public Health partnering headline values
3.4. Public Health deal upfront payments
3.5. Public Health deal milestone payments
3.6. Public Health royalty rates
Chapter 4 – Leading Public Health deals and dealmakers
4.2. Most active in Public Health partnering
4.3. List of most active dealmakers in Public Health
4.4. Top Public Health deals by value
Chapter 5 – Public Health contract document directory
5.2. Public Health partnering deals where contract document available
Chapter 6 – Public Health dealmaking by therapeutic target
6.2. Deals by Public Health therapeutic target
Appendix 1 – Directory of Public Health deals by company A-Z 2012 to 2018
Appendix 2 – Directory of Public Health deals by deal type 2012 to 2018
Appendix 3 – Directory of Public Health deals by stage of development 2012 to 2018
Appendix 4 – Directory of Public Health deals by technology type 2012 to 2018
Further reading on dealmaking
Deal type definitions
About Wildwood Ventures
Recent report titles from CurrentPartnering
Table of figures
Figure 1: Public Health partnering since 2012
Figure 2: Public Health partnering by deal type since 2012
Figure 3: Public Health partnering by industry sector since 2012
Figure 4: Public Health partnering by stage of development since 2012
Figure 5: Public Health partnering by technology type since 2012
Figure 6: Public Health partnering by indication since 2012
Figure 7: Public Health deals with a headline value
Figure 8: Public Health deals with upfront payment values
Figure 9: Public Health deals with milestone payment
Figure 10: Public Health deals with royalty rates
Figure 11: Active Public Health dealmaking activity– 2012 to 2018
Figure 12: Top Public Health deals by value since 2012
Do you need more information about this report before making a purchase decision or wish to customize this report to suite your requirements?
If yes, then please use the form given below and we will get in touch with you immediately.
Kindly use your official email address and contact number to ensure speedy response.